Ken Griffin Halozyme Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $52,934 - $73,360	1,400 Added 7.91%	19,100 $1 Million
Q1 2024 May 15, 2024	SELL	$33.68 - $41.95 $43,784 - $54,535	-1,300 Reduced 6.84%	17,700 $720,000
Q4 2023 Feb 14, 2024	SELL	$33.32 - $42.1 $569,772 - $719,910	-17,100 Reduced 47.37%	19,000 $702,000
Q3 2023 Nov 14, 2023	BUY	$36.46 - $44.03 $185,946 - $224,553	5,100 Added 16.45%	36,100 $1.38 Million
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $181,680 - $232,440	6,000 Added 24.0%	31,000 $1.12 Million
Q1 2023 May 15, 2023	SELL	$32.86 - $55.7 $555,334 - $941,330	-16,900 Reduced 40.33%	25,000 $954,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $368,552 - $546,848	9,200 Added 28.13%	41,900 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$38.53 - $51.78 $1.19 Million - $1.6 Million	-30,900 Reduced 48.58%	32,700 $1.29 Million

488

122M

208K

66.3K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.29B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.